|1||NCT03898180||Recruiting||Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)||
||694||All||18 Years and older (Adult, Older Adult)||NCT03898180||7902-011
|May 6, 2019||December 30, 2022||December 30, 2022||April 1, 2019||October 10, 2019||
|2||NCT03006887||Active, not recruiting||Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Subjects With Selected Solid Tumors||
||6||All||20 Years and older (Adult, Older Adult)||NCT03006887||E7080-J081-115
|January 19, 2017||June 2020||June 2020||December 30, 2016||April 24, 2019||
† Study has passed its completion date and status has not been verified in more than two years.